Tumor induced senescent and suppressor T cells - a novel mechanism of immune evas
肿瘤诱导的衰老和抑制性T细胞——免疫逃逸的新机制
基本信息
- 批准号:7686218
- 负责人:
- 金额:$ 31.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-11 至 2013-07-31
- 项目状态:已结题
- 来源:
- 关键词:Active ImmunotherapyApoptosisApoptoticAreaBindingCD28 geneCD8B1 geneCancer PatientCell Culture TechniquesCellsClinicalCoinDataDevelopmentDiagnosticDiseaseEffector CellEtiologyFailureFamily memberFibroblastsFunctional disorderFutureGenerationsGoalsGrantHead and Neck Squamous Cell CarcinomaHead and neck structureHumanImmuneImmune responseImmune systemImmunologyImmunosuppressionImmunotherapeutic agentImmunotherapyIn VitroInterleukin-12Interleukin-2Interleukin-7LymphocyteMCL1 proteinMalignant NeoplasmsMature T-LymphocyteMediatingModelingMolecularMorbidity - disease ratePassive ImmunotherapyPathogenesisPatientsPatternPeripheral Blood LymphocytePhenotypePopulationProcessProteinsProtocols documentationQuality of lifeRegulationResearchRoleSamplingSignal TransductionSiteSolid NeoplasmSquamous cell carcinomaSuppressor-Effector T-LymphocytesT-LymphocyteTP53 geneTelomere ShorteningTestingTherapeuticTimeTranslationsTreatment ProtocolsTumor Cell LineUnited StatesUp-Regulationalternative treatmentanticancer researchbasecytokinedesignimprovedin vitro Modelin vivomelanomamortalitynovelnovel diagnosticsoutcome forecastpublic health relevanceresponsesenescencesuccesstumortumor growthtumor progression
项目摘要
DESCRIPTION (provided by applicant): Squamous cell carcinoma of the head and neck (SCCHN) remains one of the deadliest cancers in the United States. Despite many emerging new treatments there has been almost no success in improving either the morbidity or mortality of this disease. Continuing advances in immunology make immunotherapy an active area for current and future cancer research. However, the design of immunotherapeutic strategies for SCCHN requires an understanding of the tumor microenvironment. We have recently observed that a senescence-like process is involved in the dysfunction of T lymphocytes in the tumor microenvironment. Further, these cells not only have senescent features, but in addition have functional changes consistent with suppressor cells. Future success of immunotherapeutic approaches for cancer patients are dependent on the protection of T cells from such changes at the tumor site and the enhancement of their efficiency. Mcl-1, a prosurvival Bcl-2 family member, has recently been demonstrated to be required for the survival of mature T lymphocytes. Our preliminary results suggest that Mcl-1 may have a key regulatory role in the protection of T lymphocytes from tumor-induced senescence that is mediated through the pro-senescent and -apoptotic molecule, p53. Noteworthy, among the pro-survival Bcl-2 family members, Mcl-1 is the major protein to undergo significant upregulated expression in response to cytokines used for immunotherapy, such as, IL-2, IL-7, and IL-12. The current application will attempt to elucidate the role and functional mechanisms of Mcl-1 in the protection of SCCHN-associated lymphocytes from senescence at the tumor microenvironment. The underlying scientific approach will employ a model of tumor-induced senescence of T cells to further characterize the mechanisms involved in this process with an emphasis on the regulation of p53 senescent activity by Mcl-1. Further characterization of the suppressor function of these senescent T cells will be performed to better understand the impact of this process on the immune system. The translational components of this proposal will evaluate the diagnostic potential of the newly identified senescent suppressor T cells and elucidate intracellular targets for the improvement of current immunotherapeutic protocols for SCCHN. PUBLIC HEALTH RELEVANCE: Project Narrative The goal of the current project is to elucidate a new form of tumor immune evasion. By gaining a better understanding of the molecular mechanisms involved in the formation of cancer associated dysfunctional T cells new diagnostic and therapeutic regimens can be devised. The proposal centers on explaining how cancer in part evades the immune system through directly altering T cells with the goal of improving the success of emerging immune based therapies.
描述(由申请人提供):头颈部鳞状细胞癌(SCCHN)仍然是美国最致命的癌症之一。尽管出现了许多新的治疗方法,但在改善这种疾病的发病率或死亡率方面几乎没有成功。免疫学的不断进步使免疫治疗成为当前和未来癌症研究的活跃领域。然而,SCCHN免疫策略的设计需要对肿瘤微环境的理解。我们最近观察到,衰老样的过程是参与肿瘤微环境中的T淋巴细胞功能障碍。此外,这些细胞不仅具有衰老特征,而且还具有与抑制细胞一致的功能变化。癌症患者免疫治疗方法的未来成功取决于保护T细胞免受肿瘤部位的这种变化以及增强其效率。Mcl-1是Bcl-2家族中的一个成员,最近被证明是成熟T淋巴细胞存活所必需的。我们的初步结果表明,Mcl-1可能有一个关键的调节作用,在保护T淋巴细胞从肿瘤诱导的衰老,介导的促衰老和凋亡分子,p53。值得注意的是,在促存活Bcl-2家族成员中,Mcl-1是响应于用于免疫治疗的细胞因子(例如IL-2、IL-7和IL-12)而经历显著上调表达的主要蛋白质。本申请将试图阐明Mcl-1在肿瘤微环境中保护SCCHN相关淋巴细胞免于衰老的作用和功能机制。潜在的科学方法将采用肿瘤诱导的T细胞衰老模型来进一步表征这一过程中涉及的机制,重点是Mcl-1对p53衰老活性的调节。将对这些衰老T细胞的抑制功能进行进一步表征,以更好地了解这一过程对免疫系统的影响。该提案的翻译部分将评估新鉴定的衰老抑制性T细胞的诊断潜力,并阐明改善SCCHN当前免疫方案的细胞内靶点。 公共卫生相关性:项目叙述当前项目的目标是阐明一种新形式的肿瘤免疫逃避。通过更好地理解与癌症相关的功能障碍性T细胞形成相关的分子机制,可以设计新的诊断和治疗方案。该提案的重点是解释癌症如何通过直接改变T细胞来部分逃避免疫系统,目的是提高新兴免疫疗法的成功率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRIAN R GASTMAN其他文献
BRIAN R GASTMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRIAN R GASTMAN', 18)}}的其他基金
Mechanisms of nuclear Mcl-1 mediated chemoresistance
核 Mcl-1 介导的化疗耐药机制
- 批准号:
10312133 - 财政年份:2020
- 资助金额:
$ 31.13万 - 项目类别:
Tumor induced senescent and suppressor T cells - a novel mechanism of immune evas
肿瘤诱导的衰老和抑制性T细胞——免疫逃逸的新机制
- 批准号:
8234371 - 财政年份:2011
- 资助金额:
$ 31.13万 - 项目类别:
Tumor induced senescent and suppressor T cells - a novel mechanism of immune evas
肿瘤诱导的衰老和抑制性T细胞——免疫逃逸的新机制
- 批准号:
8121606 - 财政年份:2011
- 资助金额:
$ 31.13万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
- 批准号:
10596657 - 财政年份:2021
- 资助金额:
$ 31.13万 - 项目类别:
Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
- 批准号:
10417219 - 财政年份:2021
- 资助金额:
$ 31.13万 - 项目类别:
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2015
- 资助金额:
$ 31.13万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Understanding the activation of pro-apoptotic Bcl-2 family proteins for the development of modulators of apoptosis
了解促凋亡 Bcl-2 家族蛋白的激活以开发凋亡调节剂
- 批准号:
nhmrc : 1059331 - 财政年份:2014
- 资助金额:
$ 31.13万 - 项目类别:
Project Grants
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2014
- 资助金额:
$ 31.13万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2013
- 资助金额:
$ 31.13万 - 项目类别:
Postgraduate Scholarships - Doctoral
Apoptotic Osteocytes Promote Chondrocyte Apoptosis via Soluble Factors
凋亡骨细胞通过可溶性因子促进软骨细胞凋亡
- 批准号:
251802 - 财政年份:2012
- 资助金额:
$ 31.13万 - 项目类别:
Studentship Programs
Defining the mechanism(s) by which the cellular inhibitor of apoptosis protein 2 (cIAP2) contributes to early stage atherosclerosis development by directly promoting the participation of key apoptotic pathways within lesion-associated macrophages
确定凋亡蛋白细胞抑制剂 2 (cIAP2) 通过直接促进病变相关巨噬细胞内关键凋亡途径的参与来促进早期动脉粥样硬化发展的机制
- 批准号:
191299 - 财政年份:2009
- 资助金额:
$ 31.13万 - 项目类别:
Operating Grants
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
- 批准号:
8075522 - 财政年份:2009
- 资助金额:
$ 31.13万 - 项目类别:
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
- 批准号:
7676912 - 财政年份:2009
- 资助金额:
$ 31.13万 - 项目类别: